Articles

The Public-Private Partnership for Rare Neurodegenerative Diseases will work to enhance understanding and develop treatments for rare neurodegenerative diseases.

FDA and NIH Enter Rare Neurodegenerative Diseases Partnership

FDA granted accelerated approval to Skysona (elivaldogene autotemcel), which is designed to slow the progression of neurologic dysfunction in adolescents with CALD.

FDA Approves Bluebird Bio’s $3 Million CALD Treatment

Lonza has expanded its HPAPI multipurpose suite for payload-linker manufacturing. 

Lonza Expands HPAPI Multipurpose Suite

Boehringer Ingelheim will use Virtuosi to train employees at three aseptic sites across its network.

Boehringer Ingelheim Adopts Virtuosi VR Education Platform

 Washington Editor, jillwechsler7@gmail.com.

Regulatory officials are addressing challenges in ensuring that clinical data can be relied on in making regulatory decisions. 

Clinical Trial Modernization Raises FDA Compliance Issues

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

CytoReason Announces Expanded Collaboration Deal with Pfizer

Otsuka announced that the EC has approved Lupkynis as the first oral treatment for active lupus nephritis. 

EC Approves Lupkynis for Treatment of Active Lupus Nephritis

Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility. 

Civica to Invest $27.8 Million in New Testing Facility

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence. 

Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery and Development

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

All News